Long-Term use of ticagrelor in patients with prior myocardial infarction

New England Journal of Medicine

Volumn 372, Issue 19, 2015, Pages 1791-1800

  Bonaca, Marc P ^a   Bhatt, Deepak L ^a   Cohen, Marc ^b   Steg, Philippe Gabriel ^c,d   Storey, Robert F ^e   Jensen, Eva C ^f   Magnani, Giulia ^a   Bansilal, Sameer ^g   Fish, M Polly ^a   Im, Kyungah ^a   Bengtsson, Olof ^f   Ophuis, Ton Oude ^h   Budaj, Andrzej ⁱ   Theroux, Pierre ^j   Ruda, Mikhail ^k   Hamm, Christian ^l   Goto, Shinya ^m   Spinar, Jindrich ⁿ   Nicolau, José Carlos ^o   Kiss, Robert G ^p   Murphy, Sabina A ^a   Wiviott, Stephen D ^a   Held, Peter ^f   Braunwald, Eugene ^a   Sabatine, Marc S ^a   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^c BICHAT HOSPITAL   (France)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h CANISIUS WILHELMINA HOSPITAL   (Netherlands)

ⁱ GROCHOWSKI HOSPITAL   (Poland)

^j MONTREAL HEART INSTITUTE   (Canada)

^k INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^l JUSTUS LIEBIG UNIVERSITY   (Germany)

^m TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p Military Hospital   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

AGED; ARTICLE; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GOUT; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; THROMBOSIS; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; RISK; SECONDARY PREVENTION;

ADENOSINE; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK; SECONDARY PREVENTION;

EID: 84928944621     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1500857     Document Type: Article

References (26)

1. The atlas of heart disease and stroke. Geneva: World Health Organization, 2004 (http://www.who.int/cardiovascular-diseases/resources/atlas/en).
2. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics - 2015 update: a report from the American Heart Association. Circulation 2015;131(4):e29-e322.
3. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-7.
4. Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010;31:2755-64.
5. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015 January 13 (Epub ahead of print).
6. Kapoor JR. Platelet activation and atherothrombosis. N Engl J Med 2008;358:1638.
7. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. [Errata, N Engl J Med 2001;345:1506, 1716.]
9. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.
10. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
11. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
12. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:2354-94.
13. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
14. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127(4):e362-e425. [Erratum, Circulation 2013;128(25):e481.]
15. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
16. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47.
17. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014;167:437-44.
18. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-72.
19. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008;51:2028-33.
20. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a pre-specified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet 2012;380:1317-24.
21. Wiviott SD, White HD, Ohman EM, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-STsegment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 2013;382:605-13.
22. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
23. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-8.
24. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66.
25. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126(25):e354-e471. [Erratum, Circulation 2014;129(16):e463.]
26. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.